comparemela.com

Latest Breaking News On - James dodwell - Page 3 : comparemela.com

Investegate | Company Announcement

Investegate announcements from Publication of EMTN Suppl.Prospcts

United kingdomUnited kingdom generalCity ofJames dodwellTim foleyNick stoneFinancial conduct authorityFinancial conduct authority national storage mechanismEuro medium term note programmeLondon unitedGlaxosmithkline capitalMedium term noteNational storage mechanismElectronic submission systemKingdom media

GSK : Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial - Form 6-K -December 18, 2023 at 06:38 am EST

a1192x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER.

United kingdom generalUnited kingdomTreasure islandUnited statesCity ofJames dodwellTim foleyCamilla campbellJeff mclaughlinMick readeyDan smithHesham abdullahJosh williamsLyndsay meyerSteph mountifieldKathleen quinn

GSK : Japan s Ministry of Health, Labour and Welfare accepts Arexvy regulatory application to prevent RSV disease in adults aged 50-59 at increased risk - Form 6-K -December 12, 2023 at 06:09 am EST

a3878w UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER.

United statesCity ofUnited kingdomUnited kingdom generalSteph mountifieldCamilla campbellJosh williamsTim foleyRichard osei yeboahSimon mooreJ clin virolJeff mclaughlinMick readeyNick stoneJames dodwellKathleen quinn

GSK : Phase III RUBY trial of Jemperli (dostarlimab) plus chemotherapy meets endpoint of overall survival in patients with primary advanced or recurrent endometrial cancer - Form 6-K -October 30, 2023 at 07:13 am EDT

a6268r UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER.

United kingdomUnited statesCity ofTreasure islandUnited kingdom generalNick stoneTim foleyCamilla campbellMick readeyJames dodwellSteph mountifieldKathleen quinnJeff mclaughlinLyndsay meyerDan smithJosh williams

GSK : ViiV Healthcare receives approval from China s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) used in combination with Rekambys (rilpivirine), the first and only complete long-acting HIV-1 injectable treatment - Form 6-K -October 26, 2023 at 08:20 am EDT

a3337rgskplcedgar UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,.

United kingdomUnited statesNorth carolinaCity ofYong junUnited kingdom generalCamilla campbellJeff mclaughlinDeborah waterhouseSteph mountifieldMick readeyLyndsay meyerNick stoneJames dodwellNicola andreSarah clements

vimarsana © 2020. All Rights Reserved.